Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
7
×
detroit blog main
7
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
7
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
pfizer
abbvie
cancer
clinical trials
medicare
merck
astrazeneca
cancer immunotherapy
celgene
drug prices
eli lilly
investing
What
drug
7
×
bio
roundup
news
approval
approved
companies
conference
disease
liver
nash
new
prices
race
week
adu
advanced
advantages
alnylam’s
alzheimer’s
annual
assessed
attention
away
bar
beats
bff
bids
biogen
biogen’s
biopharmaceutical
biotech
bringing
brings
ceos
communities
complicated
convo
dc
deals
Language
unset
Current search:
drug
×
biotech
×
" detroit blog main "
×
" san francisco top stories "
×
" bristol-myers squibb "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
